Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2013 1
2015 1
2017 2
2018 1
2019 1
2021 4
2022 4
2023 6
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

18 results

Results by year

Filters applied: . Clear all
Page 1
Endocannabinoid System in Polycystic Kidney Disease.
Klawitter J, Sempio C, Jackson MJ, Smith PH, Hopp K, Chonchol M, Gitomer BY, Christians U, Klawitter J. Klawitter J, et al. Among authors: gitomer by. Am J Nephrol. 2022;53(4):264-272. doi: 10.1159/000522113. Epub 2022 Mar 9. Am J Nephrol. 2022. PMID: 35263737 Free PMC article.
Kynurenines in polycystic kidney disease.
Klawitter J, Jackson MJ, Smith PH, Hopp K, Chonchol M, Gitomer BY, Cadnapaphornchai MA, Christians U, Klawitter J. Klawitter J, et al. Among authors: gitomer by. J Nephrol. 2023 Jan;36(1):83-91. doi: 10.1007/s40620-022-01361-6. Epub 2022 Jul 22. J Nephrol. 2023. PMID: 35867237 Free PMC article.
Immune checkpoint activity regulates polycystic kidney disease progression.
Kleczko EK, Nguyen DT, Marsh KH, Bauer CD, Li AS, Monaghan MT, Berger MD, Furgeson SB, Gitomer BY, Chonchol MB, Clambey ET, Zimmerman KA, Nemenoff RA, Hopp K. Kleczko EK, et al. Among authors: gitomer by. JCI Insight. 2023 Jun 22;8(12):e161318. doi: 10.1172/jci.insight.161318. JCI Insight. 2023. PMID: 37345660 Free PMC article.
Statin therapy in patients with early-stage autosomal dominant polycystic kidney disease: Design and baseline characteristics.
Gitomer BY, Wang W, George D, Coleman E, Nowak KL, Struemph T, Cadnapaphornchai MA, Patel NU, Jovanovich A, Klawitter J, Farmer B, Ostrow A, You Z, Chonchol M. Gitomer BY, et al. Contemp Clin Trials. 2024 Feb;137:107423. doi: 10.1016/j.cct.2023.107423. Epub 2023 Dec 25. Contemp Clin Trials. 2024. PMID: 38151173 Free article. Clinical Trial.
Therapeutic Area Data Standards for Autosomal Dominant Polycystic Kidney Disease: A Report From the Polycystic Kidney Disease Outcomes Consortium (PKDOC).
Perrone RD, Neville J, Chapman AB, Gitomer BY, Miskulin DC, Torres VE, Czerwiec FS, Dennis E, Kisler B, Kopko S, Krasa HB, LeRoy E, Castedo J, Schrier RW, Broadbent S. Perrone RD, et al. Among authors: gitomer by. Am J Kidney Dis. 2015 Oct;66(4):583-90. doi: 10.1053/j.ajkd.2015.04.044. Epub 2015 Jun 15. Am J Kidney Dis. 2015. PMID: 26088508 Review.
CD8+ T cells modulate autosomal dominant polycystic kidney disease progression.
Kleczko EK, Marsh KH, Tyler LC, Furgeson SB, Bullock BL, Altmann CJ, Miyazaki M, Gitomer BY, Harris PC, Weiser-Evans MCM, Chonchol MB, Clambey ET, Nemenoff RA, Hopp K. Kleczko EK, et al. Among authors: gitomer by. Kidney Int. 2018 Dec;94(6):1127-1140. doi: 10.1016/j.kint.2018.06.025. Epub 2018 Sep 21. Kidney Int. 2018. PMID: 30249452 Free PMC article.
18 results